Fertility and Sterility/LinkedIn
Oct 12, 2025, 07:57
Relugolix Combo Therapy in Fibroids and Adenomyosis – Fertility and Sterility
Fertility and Sterility shared a post on LinkedIn about a paper by William H. Catherino et al. published in Fertility and Sterility:
“Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: Subgroup analysis of LIBERTY 1 and LIBERTY 2
Title: Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2
Authors: William H. Catherino, Ayman Al-Hendy, Souhil Zaim, Nadia Bouzegaou, Roberta Venturella, Elizabeth A. Stewart, Rui Wu, Silvia Vannuccini, Julie S. Perry, Viatcheslav G. Rakov, Malcolm G. Munro
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Dec 21, 2025, 02:15Siddhartha Yadav: New ASCO Guideline for Managing Cancer During Pregnancy
-
Dec 21, 2025, 01:56New Patient Resource on Thyroid Issues in Pregnancy – RCOG
-
Dec 21, 2025, 01:49CDC Releases 2024 Pregnancy Mortality Data – Preeclampsia Foundation
-
Dec 21, 2025, 01:30Caitlin Wyrwoll: New Insights on Maternal Health and Extreme Heat
-
Dec 20, 2025, 10:57Clare Pin-Chia Huang: New Research Links Maternal Diabetes to Pregnancy Risks
-
Dec 20, 2025, 10:53Evaluating Maternal and Neonatal Health in Rheumatoid Arthritis Pregnancies – Hiroki Ozawa
-
Dec 20, 2025, 10:36Enhancing Care for Women Facing Recurrent Pregnancy Loss – SOGC
-
Dec 20, 2025, 05:00Ilana Ferhadian: Celebrating Book Launch
-
Dec 19, 2025, 16:21Launch of National Fertility Plan Marks Public Health Milestone – Collectif BAMP Association